| (USD) | Dec 2022 | Q/Q |
|---|---|---|
| Revenue | 217.3MM | +3% |
| Operating Income | -141.8MM | +19% |
| Operating Expenses | 359MM | - |
| Net Income | -142.6MM | +17% |
| R&D | 87.9MM | +34% |
| G&A | 143.8MM | -3% |
| Interest Expense | 2.8MM | +18% |
Short Volume Ratio = Short Volume / All Volume. Source of Short Volume data comes from
FinraMoving Average Convergence/Divergence oscillator (MACD) is one of the simplest and most effective momentum indicators available.
Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. RSI oscillates between zero and 100. According to Wilder, RSI is considered overbought when above 70 and oversold when below 30.
Baron Funds, an investment management company, released its “Baron Health Care Fund” first quarter 2024 investor letter. A copy of the same can be downloaded here. The fund advanced 8.92% (Institutional Shares) in the quarter compared to an 8.52% gain for the Russell 3000 Health Care Index (benchmark) and a 10.56% increase for the S&P […]
Michael Brophy, the Chief Financial Officer of Natera Inc (NASDAQ:NTRA), has sold 1,523 shares of the company on April 23, 2024, according to a recent SEC filing.
Steven Chapman, CEO and President of Natera Inc (NASDAQ:NTRA), has sold 2,552 shares of the company on April 23, 2024, according to a recent SEC Filing.
AUSTIN, Texas, April 22, 2024--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA (cfDNA) and genetic testing, today announced that it has passed a significant milestone with the publication of more than 200 peer-reviewed papers highlighting Natera’s technology in the scientific literature.
Steven Chapman, CEO and President of Natera Inc (NASDAQ:NTRA), has sold 6,816 shares of the company on April 15, 2024, according to a recent SEC Filing.
Persistent inflation and an escalating war in the Middle East are putting pressure on the stock market while giving investors an impetus to find safe havens. The S&P 500 has lost more than 3.5% so far this month, as nervous investors held back from stocks. But not all stocks are losing traction in the face of these headwinds. Some stocks offer investors an array of supportive factors, strengths that can see them through a wide range of powerful difficulties. The Smart Score tool, from TipRanks,
Key Insights Using the 2 Stage Free Cash Flow to Equity, Natera fair value estimate is US$119 Natera's US$96.71 share...
AUSTIN, Texas, April 11, 2024--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA (cfDNA) testing, today announced a new publication from the ProActive study in Transplantation supporting the use of the Prospera Kidney donor-derived cfDNA (dd-cfDNA) test as a leading indicator of kidney transplant rejection. The published manuscript can be found here.
In this article, we discuss 11 best biotech ETFs to buy. If you want to skip our discussion on the biotech industry, head over to 5 Best Biotech ETFs To Buy. The new era in biotech is defined by the convergence of biology, data, and artificial intelligence. According to The Journal of mHealth, the focus […]
AUSTIN, Texas, April 08, 2024--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA (cfDNA) testing, today announced the publication of two major studies, DTRT-2 and Trifecta-Heart, showcasing the ability of the Prospera Heart donor-derived cfDNA (dd-cfDNA) test to detect rejection in adult and pediatric heart transplant recipients. These are the second and third peer-reviewed publications evaluating Natera’s technology for use in heart transplantation.